Business Wire

The Second Season of Sailing into the Future. Together Is About to Start

20.2.2023 12:00:00 EET | Business Wire | Press release

Share

Six regattas, the desire to excel, to continue to think about sustainability, to improve teamwork: together with ocean sailor Albert Bona, IBSA’s project Sailing into the Future. Together returns to the sea for its second season. It will be an extremely demanding year, with over 13,000 miles to sail between an ocean and epic seas: from the Atlantic to the Bay of Biscay, to the English Channel, to the Celtic Sea and the Mediterranean.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005645/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Skipper Alberto Bona on the Class40 IBSA (©IBSA | Matteo Garrone)

The year 2022 was exciting”, recalled Albert Bona. “The first six months spent preparing our boat, studying, training both myself and an ad hoc team; then the Route du Rhum, wonderful, enlightening, difficult and incredibly demanding; a regatta that left me with a great desire to go on, with a craving for more ocean and other seas to navigate. I’m ready, the new challenges are many, as are the miles to navigate; a lot of work will have to be done to always have the boat in its best conditions”.

We are ready for a new sporting season, which – while definitely being very demanding – we are sure will also give us great emotions”, stated George Pisani, Vice President Southern Europe of IBSA and Leader of the project Sailing into the Future. Together . “The Route du Rhum was a crucial test bench, an experience that allowed us to test not only the new Class40 IBSA, but our entire team. We now start 2023 with even greater enthusiasm for the competitions awaiting Alberto and his new crew, united and determined to do better and better”.

In the second season, the Class40 IBSA will cross the Atlantic three times, while experiencing a new boat formation, with the building of a crew. “This year’s calendar includes a series of very tough races, designed for a team, rather than for solo sailing. This will be a challenge within a challenge, and we will have the opportunity to reflect, together with IBSA, upon many new topics: besides sustainability, teamwork and crew preparation and management”, explained Bona.

The first is the RORC 600 , starting on February 20: an extraordinary 600-mile “slalom” between the Caribbean islands, starting and finishing in Antigua. It will be the official debut of the Class40 IBSA in a crew regatta, which will see Alberto Bona on board with his friend-opponent Luke Berry, the French owner of a twin Class40, the no. 1 project of Sam Manuard’s Mach 5. As well as Alberto’s friend, Berry is an experienced navigator in this category and – in the full spirit of sharing among oceanic sailors – will be the protagonist in his former adversary’s cockpit. “Together”, clarified Bona, “we will be able to make the boat express its top potential”. On board the Class40 IBSA for the RORC 600 Caribbean there will also be Alberto’s team manager, Luca Bertacchi, and Spanish sailor Pablo Santurde del Arco – who will be a member of the team also in the other regattas of the season – will make his debut. Santurde has a great deal of sailing experience, and has achieved several wins in the Class40 double championship. “I’ve been working with Pablo for months”, continued Bona, “and I think he’s a great choice for me”.

With a view to sustainability – and to “clock up miles” once again – the Class40 IBSA will return to Europe to participate in the Atlantic Challenge , a two-leg regatta Guadeloupe-Horta (Azores Islands)-La Rochelle: 3,500 miles of navigation which will allow the hull and the team to return to Europe and to IBSA’s home, in Brittany. With the departure of the first leg on April 1 and the arrival expected within about 20 sailing days, the Défi Atlantique is the first ocean test bench of 2023 for the IBSA team, who will participate in the regatta with a crew of three: besides Alberto and Pablo, the third navigator is being selected.

In June, the Class40 IBSA will be the protagonist of one of the most complex and fascinating regattas for North-loving sailors: the Normandy Channel , a 1000-mile race for 2 – with Alberto and Pablo on board – starting and finishing in Caen; a route between lighthouses, capes and islands in the Celtic Sea. It will be the boat’s first encounter with the Fastnet Rock this year, but she will push even further north up the Irish coast, along the St. George Channel, where she will find breath-taking views, challenging conditions and plenty of cartography to finish a still little-known regatta in Italy, but wonderful to experience and tell.

Following an extremely ambitious programme, in July IBSA will first go back to the ocean, and then it will face the legend: after transferring the boat to the Atlantic coast of Brittany, at the end of June Alberto Bona and Pablo Santurde will participate in the Le Sables-Horta-Le Sables , another 3,000 miles of ocean, this time in double, with two stages to be sailed in about two weeks. But it will not be enough, because only a week later Alberto, Pablo and a third member of the crew will participate in the legendary Rolex Fastnet Race , one of the toughest, most iconic and best-loved regattas for sailors from all over Europe, departing from Cowes, on the Isle of Wight, in Great Britain, and arriving in Cherbourg-en-Cotentin, France, after rounding (for the second time this season for the Class40 IBSA) the legendary lighthouse on the Irish coast.

The end of the summer will be used for training and test regattas, and will see the presence of Alberto Bona at the two main Italian nautical events: the Genoa Boat Show and the Barcolana, in view of the last major undertaking awaiting him in 2023: the second half of the year, indeed, will be entirely dedicated to the Transat Jacques Vabre , the great objective of the season, an event eagerly awaited by all European ocean sailors. Starting from Le Havre on October 29, the regatta will end in Martinique after 4,250 miles of navigation with a crew of two.

It will be a demanding season, one which I would define “herculean”, also considering that we will go far north twice. Many ocean sailors will make the same choices I made in terms of calendar, and therefore there will be more opportunities to compete and improve in view of the Transat Jacques Vabre. The Route du Rhum left me with great determination and a desire to improve myself. These months we have been working a lot on the boat, the sails, the electronics. We will make further improvements and we will all work hard to have a well-functioning team, one characterised by important additions, compared to last season. Thirteen thousand theoretical miles is a lot aboard a Class 40, but I have only one thing to say: I have an incredible desire to start and make the Class 40 IBSA run”, concluded Bona.

***

THE PROJECT: Sailing into the Future. Together started in January 2022; the partnership between IBSA and Alberto Bona was born on common bases and values, and aims to use sailing as a vehicle for corporate communication, towards the market and the nautical world. Ingenuity, courage, innovation, responsibility are elements that unite IBSA and Alberto, and the oceanic challenge, in addition to the sporting race, also metaphorically represents the company’s history, philosophy and vision, which are always oriented towards the future and are part of a path that brings IBSA increasingly closer to the topics of environmental and social sustainability, inclusion and integration. The Route du Rhum was the first stage of the three-year programme Sailing Into The Future. Together, which the Swiss pharmaceutical company started with Bona and which continues in 2023 with a busy calendar of regattas, including the Rolex Fastnet Race and the Transat Jaques Vabre.

THE BOAT: The boat with which Alberto Bona participated in the Route du Rhum in November is a latest generation Class40, with a scow bow. Designed by French naval architect Sam Manuard and built by the JPS Production shipyard, the boat is a Mach 5 model, the latest evolution of Manuard’s Class40.

The characteristics: rounded bow, created with the aim of increasing performance while running; water lines and appendages designed to make the hull an all-round fast even upwind; large and protected cockpit to face navigation in the most comfortable and safe positions possible.

THE SKIPPER: Alberto Bona is from Turin, and has a degree in philosophy. As a university student, he won the Panerai trophy with Stormvogel, fast ULDB and historic boat with which he crossed the Atlantic Ocean for the first time, winning the ARC with a New Zealand crew. In 2012 he took part in the Minitransat, finishing 5th, one of the best Italian results ever in this category. In 2015, he switched to the prototype category Mini 6.50 with Promostudi La Spezia: he won the Italian championship and finished second in the ocean crossing Les Sables-Azores. In 2017 he discovered the Class40: on Giovanni Soldini’s formerTelecom Italia, he participated in the Transat Jacques Vabres, where he was forced to withdraw when he was in sixth place. In 2019 he was aboard the Maserati Multi 70 trimaran, one of the fastest boats in the world, where he practiced on the foils before moving on to the Figaro Beneteau 3, aboard which he participated in the Solitaire; the only Italian registered, he finished 7th among the rookies in the first year and 16th overall in 2020. In 2021 he won the Italian offshore team title and the Europeans in mixed doubles aboard the Figaro 3. In 2022 he started the new project, with the support of the IBSA Group: with the new Class40 IBSA, he participated in the Route du Rhum 2022, finishing in eighth position.

IBSA: IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

IBSA press office – Italy
Valeria Riccobono – valeria.riccobono@noesis.net – mob: +39 392 962 5892
Ornella Reccia – ornella.reccia@noesis.net – mob: +39 329 393 1922

IBSA Press Office – Switzerland
Francesca Rossini – notizie@laboratoriodelleparole.net – mob: +41 77 417 93 72

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye